Abstract
The surface antigen of hepatitis B virus (HBsAg) spontaneously aggregates into ‘empty’ virus-like particles (VLPs) in the absence of other viral components. The powerful immunogenicity of HBsAg when administered either as VLPs or as naked DNA invites its exploitation as a vector for the delivery of antigenic determinants from other organisms. Here we discuss ways in which HBsAg may be modified to derive vaccines against disease-related pathogens. We review studies demonstrating the induction of disease-protective antibody and T-cell responses induced by immunization with recombinant HBsAg vaccines, and consider how these vaccines might best be delivered. Unmodified HBsAg VLPs are licensed for use in humans as the pan-global vaccine to prevent hepatitis B virus infection, suggesting that route-tomarket for recombinant HBsAg vaccines might be simplified. Keywords: Hepatitis B surface antigen, vaccine, DNA, virus-like particle, cytotoxic T-cell, antibody
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
